slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
309,025-309,042 of 319,975
02
10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Problem1 hit
03
10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Problem1 hit
04
10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Problem1 hit
05
Includes a financial snapshot with valuation multiples and a product-level sales table.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Problem1 hit
06
The chart uses a dual-axis approach to show price (line) and volume (bars) with annotated callouts for specific events.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Market Size1 hit
07
The slide highlights the lack of analyst coverage and low float (34%) resulting in low trading volume for Taro Pharma.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Market Size1 hit
08
The slide uses a mix of historical (A) and estimated (E) data, with specific H1 comparisons.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Market Size1 hit
09
The slide uses a combination of annual historical/forecast data and half-year comparisons to explain cost structure changes.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Financials1 hit
10
Includes a detailed income statement table with Q1, Q2, H1 2012 actuals and 2012 estimates.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Financials1 hit
11
10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · Financials1 hit
12
Includes two bar charts showing historical/projected growth and a median benchmark line.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · FinancialsLoop · Pattern Hunter1 hit
13
Taro is highlighted in blue in each chart, while peers are in grey. Medians are indicated by red dashed lines.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · FinancialsLoop · Pattern Hunter1 hit
14
Includes specific footnotes regarding adjustments for peer data (e.g., Actavis, Paddock, Flomax).10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · FinancialsLoop · Pattern Hunter1 hit
15
10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · ValuationLoop · Golden Circle1 hit
16
Includes specific financial benchmarks like P/E ratios and valuation ranges relative to Sun Pharma's offer price.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · ValuationLoop · Golden Circle1 hit
17
Includes data on price bumps, offer premiums, and transaction duration.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · ValuationLoop · Golden Circle1 hit
18
Includes sensitivity tables for WACC vs Terminal EBITDA Multiple, WACC vs Implied Perpetuity Growth Rate, and WACC vs Terminal Value as a % of Enterprise Value.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · ValuationLoop · Golden Circle1 hit
19
The chart highlights a period of multiple uplift attributed to stock price appreciation ahead of product pricing increases.10 IBD presentation 2012 Taro Pharmaceutical Industries Citigroup · 10-ibd-presentation-2012-taro-pharmaceutical-industries-citigroup
Deck Investment bank Beat · ValuationLoop · Golden Circle1 hit